ArticleFrontiers in genetics2021
Barriers to Therapeutic Use of Hydroxyurea for Sickle Cell Disease in Nigeria: A Cross-Sectional Survey.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 47 citations in OpenAlex.
- Real-World Evidence of Crizanlizumab Showing Reductions in Vaso-Occlusive Crises and Opioid Usage in Sickle Cell Disease.European journal of haematology · 2025Trial
- Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial.The Lancet. Haematology · 2023Trial
- Process-related determinants of quality of care for individuals with sickle cell disease in a tertiary facility in Ghana.BMJ open · 2026Article
- Underutilisation of hydroxyurea in sickle cell disease: a global scoping review of multilevel barriers and facilitators.Journal of community genetics · 2026Review
- The role of hydroxyurea in modulating miRNA expression in sickle cell disease: molecular mechanisms and therapeutic implications.Annals of hematology · 2026Review
- Barriers to sickle cell disease care: a biopsychosocial analysis mapped to the standards of care guidelines by the sickle pan African research consortium.Journal of public health (Oxford, England) · 2026Article
- Hydroxyurea pharmacokinetics in children with sickle cell anemia across different global populations.Blood advances · 2026Article
- Beyond the Prescription: Hydroxycarbamide Utilization and Adherence Among Persons Living with Sickle Cell Disease in Rural Ghana.Patient preference and adherence · 2026Article
- Can platelet to neutrophil ratio (PNR) serve as a viable alternative tool for monitoring sickle cell disease patients on hydroxyurea in low income countries?Annals of hematology · 2025Article
- Level of Healthcare Facility and Psychosocial Factors Influence Perceived Self-Efficacy for Appropriate Use of Hydroxyurea: Experience from Caregivers of Children with Sickle Cell Disease in Tanzania.Healthcare (Basel, Switzerland) · 2025Article
- The feasibility of pharmacokinetic-based dosing of hydroxyurea for children with sickle cell anaemia in Uganda: Baseline results of the alternative dosing and prevention of transfusions trial.British journal of clinical pharmacology · 2025Article
- Adherence to Hydroxyurea Therapy for Pediatric Sickle Cell Anemia in Tanzania: Evidence from Bugando Medical Centre.International journal of environmental research and public health · 2025Article
- The feasibility of pharmacokinetic-based dosing of hydroxyurea for children with sickle cell anaemia in Uganda: Baseline results of the alternative dosing and prevention of transfusions trial.British journal of clinical pharmacology · 2025Article
- Building capacity for pediatric hematological diseases in Sub-Saharan Africa.Blood advances · 2025Review
- CYP2D6 Pharmacogenetics in Nigerian Sickle Cell Disease: Phase 1 of Implementing Pharmacogenomics Testing for Effective Care and Treatment in Africa (iPROTECTA) program.Gates open research · 2025Article
- Pharmacokinetic-Guided Hydroxyurea to Reduce Transfusions in Ugandan Children with Sickle Cell Anemia: Study Design of the Alternative Dosing And Prevention of Transfusions Trial.Acta haematologica · 2025Article
- Caregivers' beliefs about hydroxyurea influence its usage among children with sickle cell disease: a cross-sectional study in Dar-es-Salaam, Tanzania.The Pan African medical journal · 2025Article
- Article
- Computational screening of phytochemicals present in some Nigerian medicinal plants against sickle cell disease.Scientific reports · 2024Article
- CRISPR/Cas9 in the treatment of sickle cell disease (SCD) and its comparison with traditional treatment approaches: a review.Annals of medicine and surgery (2012) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Emmanuel Chide OkochaHaematology Department, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria.
Joyce GyamfiGlobal Health Program and Department of Social and Behavioral Sciences, NYU School of Global Public Health, New York, NY, United States.
Nessa RyanGlobal Health Program and Department of Social and Behavioral Sciences, NYU School of Global Public Health, New York, NY, United States.
Oluwatoyin BabalolaDepartment of Biotechnology, Chrisland University, Abeokuta, Nigeria.
Eno-Abasi EtukCentre of Excellence for Sickle Cell Disease Research and Training (CESRTA), University of Abuja, Abuja, Nigeria.
Reuben ChianumbaCentre of Excellence for Sickle Cell Disease Research and Training (CESRTA), University of Abuja, Abuja, Nigeria.
Maxwell NwegbuCentre of Excellence for Sickle Cell Disease Research and Training (CESRTA), University of Abuja, Abuja, Nigeria.
Hezekiah IsaCentre of Excellence for Sickle Cell Disease Research and Training (CESRTA), University of Abuja, Abuja, Nigeria.
Anazoeze Jude MaduDepartment of Haematology and Immunology, College of Medicine, University of Nigeria, Ituku-Ozalla Campus, Enugu, Nigeria.
Samuel AdegokeDepartment of Paediatrics and Child Health, Obafemi Awolowo University, Ile-Ife, Nigeria.
Uche Nnebe-AgumanduCentre of Excellence for Sickle Cell Disease Research and Training (CESRTA), University of Abuja, Abuja, Nigeria.
Biobele BrownDepartment of Paediatrics, College of Medicine, University of Ibadan and University College Hospital, Ibadan, Nigeria.
Emmanuel PeprahGlobal Health Program and Department of Social and Behavioral Sciences, NYU School of Global Public Health, New York, NY, United States.
Obiageli E NnoduCentre of Excellence for Sickle Cell Disease Research and Training (CESRTA), University of Abuja, Abuja, Nigeria.
University of Abuja · NGNnamdi Azikiwe University Teaching Hospital · NGObafemi Awolowo University · NGUniversity College Hospital, Ibadan · NGUniversity of Nigeria Teaching Hospital · NG
Funding
Sickle Pan African Research Consortium NigEria (SPARC-NEt)U01HL156942 · NHLBI · UNIVERSITY OF ABUJA · PI NNODU, OBIAGELI EUNICE · 2021 to 2025
$1.3MNHLBI NIH HHS U01 HL156942
Abstract
PubMed holds no abstract for this paper.
Indexed as
adoptionhealth care workershydroxyureaNigeriasickle cell diasease
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.